drugset / Trial / NCT02665637

Study Comparing Pharmacokinetics, Safety and Immunogenicity of CT-P6 and US-licensed Herceptin

NCT02665637

Phase 1 Completed 70 enrolled Celltrion
RandomizedParallel-groupDouble-blind

Summary

This is a double-blind, two-arm, parallel-group, single-dose study.

Timeline

Start
2015-12
Primary completion
2016-04
Completion
2016-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Trastuzumab Monoclonal antibody Intravenous

Indications

No indication recorded.